Skip to main content

Table 1 Number of participants screened, enrolled, and finishing follow-up and characteristics at baseline as part of therapeutic efficacy monitoring in Angola, 2015

From: Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

 

Benguela

Zaire

Lunda Sul

ASAQa

ALa

ALa

DPb

DPb

ASAQa

Screened, n

445

443

150

223

318

225

 Enrolled, n

101

101

104

102

100

78

 Lost to follow up, n (%)

20 (20)

11 (11)

7 (7)

12 (12)

14 (14)

9 (12)

 Excluded, n (%)

8 (8)

5 (5)

4 (4)

6 (6)

10 (10)

13 (17)

 Reached study endpoint, n (%)

73 (72)

85 (84)

93 (89)

84 (82)

76 (76)

56 (72)

Participant characteristics at baseline

 Median age, years (range)

5.0 (0.7–12)

6.4 (1–12)

3.0 (0.6–5)

2.8 (0.6–5)

2.8 (0.5–5)

3.2 (0.5–5)

 Median weight, kg (range)

16 (6–37)

18 (8–42)

13 (7–19)

13 (6–19)

12 (6–21)

12 (7–18)

 Percent female

40%

40%

51%

53%

42%

58%

 Median day 0 parasitemia, parasites/µL (range)

29,487 (1051–99,507)

20,151 (1003–92,733)

47,766 (2034–195,529)

48,049 (2003–187,777)

7266 (2000–180,903)

16,071 (2000–161,333)

 Median day 0 hemoglobin, g/dL (range)

10.3 (5.2–13.3)

10.2 (5.4–13.5)

10.2 (5.7–13.6)

10.0 (6–13.3)

9.4 (5.1–13.5)

9.2 (5.5–13.6)

  1. ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
  2. a28-day follow-up
  3. b42-day follow-up